Vorapaxar, rivaroxaban up for review

Candace Stuart | | Cardiovascular Business | Interventional Cardiology

The FDA’s Cardiovascular and Renal Drugs Advisory Committee faces a full docket of applications for treatments for acute coronary syndrome and other diseases in January and February.

The panel will discuss a new drug application (NDA) Jan 15 for vorapaxar sulfate (Zontivity, Merck) to reduce atherothrombotic events in patients with a history of MIs. Vorapaxar plus aspirin has been shown to reduce the risk of cardiovascular events in atherosclerosis patients but it may carry bleeding risks.

Panelists also will review of a supplemental NDA Jan. 16 for rivaroxaban, a factor Xa inhibitor. Janssen Pharmaceuticals is seeking approval for rivaroxaban (Xarelto) to reduce the risk of thrombotic cardiovascular events in patients in the first 90 days after experiencing an acute coronary syndrome (ACS).

The FDA approved rivaroxaban in July 2011 to reduce the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE) after knee or hip replacement surgery, and in November 2011 it was approved to reduce the risk of stroke in people who have nonvalvular atrial fibrillation. The agency expanded approval to include treating DVT or PE and to reduce the risk of recurrent DVT and PE following initial treatment.

But the drug has faced headwinds in the U.S. for use in ACS patients.

The panel will reconvene Feb. 12 to review an NDA for the antiplatelet drug cangrelor (The Medicines Company) to reduce the risk of stent thrombosis and other thrombotic cardiovascular events in patients with coronary artery disease undergoing PCI. The Medicines Company proposes that cangrelor, an intravenous adenosine diphosphate–receptor antagonist, be prescribed to maintain P2Y12 inhibition in at-risk patients when oral P2Y12 therapy is interrupted due to surgery.

In the CHAMPION-PHOENIX trial, cangrelor significantly reduced the rate of ischemic events, including stent thrombosis, during PCI, with no significant increase in severe bleeding.

The panel also will discuss a license application for serelaxin injection (Novartis) to improve the symptoms of acute heart failure on Feb. 13.

Candace Stuart, Contributor

Related Content

Cardiologists reflect on developing primary PCI in face of criticism and pushback
How TAVR valve choice impacts outcomes when treating type 1 bicuspid AS
IVUS-guided PCI reduces risks in patients with diabetes
Medtronic using AI to identify more TAVR patients in need
SAVR linked to higher 10-year survival rate than TAVR for low-risk patients
LAAC with Watchman FLX reduces bleeding risks after AFib ablation

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."